# LINC01996 suppresses non-small cell lung cancer proliferation and metastasis by orchestrating the miR-12115/CNRIP1/Ras signaling axis. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cnrip1-cannabinoid-receptor-protein-cancer-research-findings/ > **Published:** 2026-04-29T05:01:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T09:59:35-04:00 > **Clinical Summary:** New preclinical research identifies CNRIP1, a cannabinoid receptor-interacting protein, as a potential tumor suppressor in lung cancer through novel RNA mechani --- CED Clinical Relevance  #56Monitored Relevance Evidence Brief | CED ClinicResearchers identify a long non-coding RNA that regulates cannabinoid receptor-interacting protein expression in lung cancer through microRNA mechanisms. Cnrip1Lung CancerBasic ScienceCannabinoid ProteinsLaboratory Research Researchers identify a long non-coding RNA that regulates cannabinoid receptor-interacting protein expression in lung cancer through microRNA mechanisms. What This Study Teaches Us This study demonstrates that LINC01996 acts as a competitive endogenous RNA that sequesters miR-12115, preventing it from suppressing CNRIP1 (cannabinoid receptor-interacting protein 1). The research provides mechanistic insight into how endocannabinoid-related proteins may influence cancer progression through complex RNA regulatory networks. Why This Matters CNRIP1 emerges as a potential tumor suppressor in lung cancer, suggesting that proteins involved in cannabinoid signaling pathways may have broader roles in cancer biology than previously understood. This finding could inform future research into how cannabis-derived compounds interact with endogenous cannabinoid-related proteins in cancer contexts. Study Snapshot Study Type Laboratory and Animal Study Population Non-small cell lung cancer tissues, cell lines, and xenograft mouse models Intervention LINC01996 overexpression Comparator Control groups without overexpression Primary Outcome Cell proliferation, migration, epithelial-mesenchymal transition, and tumor progression Key Finding LINC01996 suppressed cancer progression by regulating miR-12115/CNRIP1 signaling pathway Journal Clinical & Experimental Metastasis Year 2024 Clinical Bottom Line While this laboratory research identifies CNRIP1 as a potential tumor suppressor regulated by RNA mechanisms, it does not provide evidence for [clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) use in lung cancer treatment. The study contributes to basic science understanding of cannabinoid-related protein function in cancer biology. What This Paper Does Not Show This study does not demonstrate that [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/), cannabinoids, or any cannabis-derived therapies have anti-cancer effects in humans. The research focuses on endogenous protein regulation rather than exogenous cannabinoid intervention and provides no clinical data on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in lung cancer patients. Where This Paper Deserves Skepticism The study relies on laboratory models that may not reflect human cancer biology, and the connection between CNRIP1 regulation and clinical outcomes remains unestablished. The functional significance of the identified RNA regulatory pathway in actual lung cancer progression requires validation in larger, more diverse model systems. Dr. Caplan's Take As a cannabis clinician, I find the CNRIP1 connection intellectually interesting but clinically irrelevant for current practice. This research explores endogenous protein regulation, not therapeutic cannabinoid intervention, and provides no basis for recommending cannabis to lung cancer patients based on these findings. What a Careful Reader Should Take Away This study advances basic science understanding of how cannabinoid receptor-interacting proteins function in cancer biology through RNA regulatory mechanisms. However, it does not support [clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) use and should not be interpreted as evidence for cannabis-based lung cancer therapy. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20LINC01996%20suppresses%20non-small%20cell%20lung%20cancer%20proliferation%20and%20metastasis%20by%20orchestrating%20the%20mi...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcnrip1-cannabinoid-receptor-protein-cancer-research-findings%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcnrip1-cannabinoid-receptor-protein-cancer-research-findings%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20LINC01996%20suppresses%20non-small%20cell%20lung%20cancer%20proliferation%20and%20metastasis%20by%20orchestrating%20the%20mi...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcnrip1-cannabinoid-receptor-protein-cancer-research-findings%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[What is LINC01996 and how does it relate to lung cancer treatment?](#What_is_LINC01996_and_how_does_it_relate_to_lung_cancer_treatment) - [How does this research connect to the cannabinoid system in cancer?](#How_does_this_research_connect_to_the_cannabinoid_system_in_cancer) - [Could this discovery lead to new diagnostic or prognostic tools for lung cancer?](#Could_this_discovery_lead_to_new_diagnostic_or_prognostic_tools_for_lung_cancer) - [What is the mechanism by which LINC01996 exerts its anti-cancer effects?](#What_is_the_mechanism_by_which_LINC01996_exerts_its_anti-cancer_effects) - [Are there potential therapeutic implications for targeting this pathway?](#Are_there_potential_therapeutic_implications_for_targeting_this_pathway) - [Related](#Related) ## FAQ #### What is LINC01996 and how does it relate to lung cancer treatment? LINC01996 is a long non-coding RNA that acts as a tumor suppressor in non-small cell lung cancer (NSCLC). This study found that LINC01996 is significantly downregulated in NSCLC tissues and cell lines, and when overexpressed, it inhibits cancer cell proliferation, migration, and metastasis through regulation of cannabinoid receptor-interacting protein 1 (CNRIP1). #### How does this research connect to the cannabinoid system in cancer? The study identifies CNRIP1 (Cannabinoid receptor-interacting protein 1) as a key downstream target regulated by LINC01996. CNRIP1 interacts with [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) and appears to have tumor suppressive functions when its expression is maintained through the LINC01996/miR-12115 regulatory axis. #### Could this discovery lead to new diagnostic or prognostic tools for lung cancer? Yes, LINC01996 expression levels were associated with prognosis in NSCLC patients in this study. The research suggests that measuring LINC01996 levels could potentially serve as a biomarker for [patient outcomes](https://cedclinic.com/uk-medical-cannabis-chronic-pain-outcomes-patient-insights/), though clinical validation studies would be needed before implementation. #### What is the mechanism by which LINC01996 exerts its anti-cancer effects? LINC01996 functions as a competitive endogenous RNA (ceRNA) that “sponges” miR-12115, preventing this microRNA from suppressing CNRIP1 expression. This allows CNRIP1 levels to remain elevated, which subsequently modulates Ras signaling pathways involved in cancer progression. #### Are there potential therapeutic implications for targeting this pathway? The study demonstrates that restoring LINC01996 expression inhibits tumor growth and metastasis in mouse models. This suggests that therapeutic strategies aimed at increasing LINC01996 expression or mimicking its downstream effects on the CNRIP1/Ras pathway could potentially benefit NSCLC patients, though extensive preclinical and clinical testing would be required. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).